CAMP4 Therapeutics (CAMP) vs Greenwich LifeSciences (GLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed CAMP4 Therapeutics (CAMP) over the past year, gaining 37.0% versus a gain of 16.7%. CAMP4 Therapeutics is the larger company by market cap ($232.2 million vs $222.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | GLSI |
|---|---|---|
| Share price | $3.70 | $15.14 |
| Market cap | $232.19M | $222.23M |
| 1-day change | -3.65% | -1.62% |
| YTD return | -37.36% | -26.75% |
| 1-year return | +16.72% | +37.04% |
| 5-year return | — | -59.46% |
| EPS (TTM) | $-2.32 | $-1.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $34.10 |
| 52-week low | $2.86 | $7.78 |
| Distance from 52-week high | -52.26% | -55.60% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +185.68% | +276.49% |
| Average volume | 277.90K | 138.72K |
| Shares outstanding | 62.75M | 14.68M |
| Employees | 48 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed CAMP by 20.3 percentage points over the past year.
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
CAMP vs GLSI FAQ
Which is bigger, CAMP4 Therapeutics or Greenwich LifeSciences?
CAMP4 Therapeutics (CAMP) is larger, with a market capitalization of $232.19M compared with $222.23M for Greenwich LifeSciences (GLSI).
Which stock has performed better over the past year, CAMP or GLSI?
GLSI returned +37.04% over the past 12 months, compared with +16.72% for CAMP (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and Greenwich LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.